Table 1 Patient and treatment characteristics

Age (median/range)

73y (50–94 year)

75y (48–88 year)

Gender (male/female)

58/52 (53%/47%)

47/24 (66%/34%)

Tumor diameter (median/range)

2.2 cm (0.8–6.6 cm)*

2.6 cm (1.1–6.0 cm)^#

Tumor stage (UICC8), T1/T2

89/21 (81%/19%)

45/26 (63%/37%)

Pathological confirmation (Yes/No)

91/19 (83%/17%)

55/16 (77%/23%)

Mediastinal staging

 CT only

18 (16%)

5 (7%)

 CT + PET

52 (47%)

33 (47%)

 CT + EBUS

18 (16%)

16 (23%)

 CT + EBUS + PET

18 (16%)

17 (24%)

 CT + mediastinoscopy

3 (3%)

–

 CT + PET + mediastinoscopy

1 (1%)

–

Histology

 Adenocarcinoma

37 (34%)

23 (32%)

 Squamous cell

42 (38%)

28 (39%)

 Other

12 (11%)

4 ( 6%)

 Unknown

19 (17%)

16 (23%)

Fractionation scheme

Number of fractions

Dose per fraction

n Pat

Dose per fraction

n Pat

 1

25 Gy

5 (5%)

26–27 Gy

2 (3%)

 3

17 Gy

45 (41%)

13–18 Gy

65 (90%)^§

 5

11 Gy

43 (39%)

10–11 Gy

3 (6%)

 8

7.5 Gy

17 (16%)

6.0 Gy

1 (1%)

Doses to GTV, PTV and lung (median/ range)

 GTV D_max

84.6 (28.2–95.2) Gy

70.9 (41.5–84.6) Gy

 GTV D_mean

71.6 (26.2–84.0) Gy

62.7 (37.9–72.5) Gy

 GTV D_95%

61.9 (21.8–75.9) Gy

53.8 (33.0–64.6) Gy

 PTV D_95%

54.0 (19.0–67.1) Gy

45.3 (25.2–55.2) Gy

 Lung D_1ml

65.6 (23.6–81.0) Gy

55.5 (37.7–71.6) Gy

 Lung D_10ml

52.1 (15.8–78.9) Gy

47.5 (25.8–66.9) Gy

 Lung D_50ml

31.3 (6.9–77.7) Gy

31.6 (11.2–51.9) Gy

 Lung D_100ml

20.5 (4.5–77.0) Gy

20.5 (6.6–43.0) Gy

GTV-PTV margin

3–4 mm

3–5 mm

Tracking Mode (Fiducials/XSightLung)

15/95 (14%/86%)

6/65 (9%/91%)